Linexil® 400 mg Tablet: Each film coated tablet contains Linezolid USP 400 mg.
Linexil® 600 mg Tablet: Each film coated tablet contains Linezolid USP 600 mg.
Linexil® 100 ml Powder for Suspension: After reconstitution each 5 ml contains Linezolid USP 100 mg. Add 65 ml boiled purified water to reconstitute in 100 ml suspension.
Linexil® 300 ml IV Infusion: Each ml of supplied infusion contains Linezolid USP 2 mg.
Linezolid is a synthetic antibacterial agent. It is bacteriostatic against *enterococci* and *staphylococci* and bactericidal against most strains of *streptococci*.
Mode of actionThe oxazolidinones are protein synthesis inhibitors: they stop the growth and reproduction of bacteria by disrupting translation of messenger RNA (mRNA) into proteins in the ribosome.
PharmacokineticsAbsorption: Rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%. Therefore, linezolid may be given orally or intravenously without dose adjustment.
Distribution: Linezolid readily distributes to well-perfused tissues. The plasma protein binding of linezolid is approximately 31%.
Metabolism: Hepatic oxidation of the morpholine ring, resulting in two inactive metabolites.
Elimination: Half-life elimination in adults 4-5 hours.
Monoamine Oxidase inhibitor, Adrenergic agent, Serotonergic agent.
Over dosage Symptoms of a linezolid overdose may include weakness, or loss of balance or coordination.
Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Myelosuppression has been reported and may be dependent on duration of therapy. Discontinue the treatment if Myelosuppression reported.
Keep out of reach of children. Store in a dry place, below 25°C temperature and protected from light.